Pfizer completes $680M NextWave acquisition

Pfizer ($PFE) has completed its acquisition of NextWave Pharmaceuticals. The deal could be worth up to $680 million and gives Pfizer exclusive North American commercialization rights to Quillivant XR (controlled-release methylphenidate hydrochloride), the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. Quillivant XR was developed by NextWave in partnership with Tris Pharma, using Tris Pharma's OralXR+ platform, and was approved in the U.S. in September. It's likely to reach U.S. pharmacies in January 2013. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…